Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 9, 1998, Pages 936-944

  Kawasaki, Kentaro ^a   Hayashi, Yoshitake ^a   Wang, Yao ^b   Suzuki, Satoshi ^a   Morita, Yasushi ^a   Nakamura, Takeshi ^a   Narita, Koichi ^a   Doe, William ^c   Itoh, Hiroshi ^a   Kuroda, Yoshikazu ^a  

^a KOBE UNIVERSITY   (Japan)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Biology and Environment   (Australia)

Author keywords

Gastric cancer; Plasminogen activator inhibitor l; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH CANCER;

EID: 15444360229     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00765.x     Document Type: Article

References (47)

1. Foundation for Promotion of Cancer Research. Figures on Cancer in Japan 1995. Tokyo: Foundation for Promotion of Cancer Research, 1995.
2. Filder IJ, Gersten DW, Hart I. The biology of cancer invasion and metastasis. Adv. Cancer Res. 1978; 28: 149-250.
3. Dano K, Andresen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 1985; 44: 139-66.
4. Hart DA. Dysregulation of plasminogen activators in cancer: Potential role in invasion, metastasis and as a prognostic inhibitor. Fibrinolysis 1992; 6: 11-15.
5. Schultz RM, Yu H, Zhang JY. The role of urokinase and urokinase inhibitor in tumor cell metastasis. Fibrinolysis 1992; 6: 23-9.
6. Del Vecchio S, Stoppelli MP, Carreiro M et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels. Cancer Res. 1993; 53: 3198-206.
7. Delbalo C, Cunningham M, Vassalli D, Sappino P. Plasmin-catalyzed proteolysis in colorectal neoplasm. Cancer 1995; 74: 66-70.
8. Heiss MM, Babic R, Allgayer H et al. Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer denned by the urokinase-type activator system. J. Clin. Oncol. 1995; 13: 2084-93.
9. Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: Proenzyme, receptor and inhibitor. J. Cell Biol. 1988; 104: 801-4.
10. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activator in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 1980; 102: 196-202.
11. Jin L, Nakajima M, Nicolson GL. The general rules for gastric cancer study in surgery and pathology. Int. J. Cancer 1990; 45: 1088-95.
12. Liotta LA, Thorgeirsson UP, Garbisa S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev. 1982; 1: 277-97.
13. Roldan AL, Cubellis M, Masucci MT et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990; 9: 467-74.
14. Duffy MJ. Urokinase-rype plasminogen activator and malignancy. Fibrinolysis 1993; 7: 295-302.
15. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T. Effect of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membrane. Biochim. Biophys. Acta 1993; 1178: 55-62.
16. Saksela O, Rifkin DB. Cell-associated plasminogen activation: Regulation and physiological functions. Annu. Rev. Cell. Biol. 1988; 4: 93-126.
17. Vaheri A, Stephens RW, Salonen EM, Pollanen J, Tapiovaara H. Plasminogen activation at the cell surface matrix interface. Cell Differ. Dev. 1990; 32: 255-62.
18. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 1994; 20: 14746-50.
19. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 1994; 51: 32380-8.
20. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff D. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 1996; 134: 1563-71.
21. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 1997; 1: 58-67.
22. Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-5.
23. Behrendt N, Ronne E, Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol. Chem. 1995; 376: 269-79.
24. Gladson CL, Thompson P, Olman MA, Gillespie GY, Yacoub IZ. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am. J. Pathol. 1995; 146: 1150-60.
25. Sier CFM, Vloedgraven HJM, Ganesh S et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994; 107: 1449-56.
26. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 1993; 73: 161-95.
27. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matuo O. Plasminogen activator inhibitor 1 in human carcinoma tissues. Int. J. Cancer 1991; 48: 481-4.
28. Takai S, Yamamura M, Tanaka K et al. Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical stainings. Int. J. Cancer 1991; 48: 20-7.
29. Sier CFM, Verspaget HW, Griffioen G et al. Plasminogen activators in normal tissue and carcinomas of human oesophagus and stomach. Gut 1993; 34: 80-5.
30. Springer JE, Robbins E, Gwag BJ, Lewis ME, Baldino FJ. Non-radiographic detection of nerve growth factor receptor (NGFR) mRNA in rat brain using in situ hybridization histochemistry. J. Histochem. Cytochem. 1991; 39: 231-4.
31. Japanese Research Society for Gastric Cancer. Japanese classification of Gastric Carcinoma, First English edn. Tokyo: Kanehara and Co. Ltd, 1995.
32. Keski-Oja J, Kori K, Lohi J, Laiho M. Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin. Thromb. Hemost. 1991; 17: 231-9.
33. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis. Cancer Res. 1989; 49: 2533-53.
34. Liotta LA. Tumor invasion and metastasis. Role of the extracellular matrix. Cancer Res. 1986; 46: 1-7.
35. Liotta LA, Goldfarb RH, Brundage R, Siegel GP, Terranova V, Garbisa S. Effect of plasminogen activator, plasmin and thrombin on glycoprotein and collagenous compounds of basement membrane. Cancer Res. 1981; 41: 4629-36.
36. Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggavason K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells: Role in metastasis. Int. J. Cancer 1982; 30: 669-73.
37. Noguchitakino M, Endo Y, Yonemura Y, Sasaki T. Relationship between expression of plasminogen activator system and metastatic ability in human cancers. Int. J. Oncol. 1996; 8: 97-105.
38. Park IK, Kim BJ, Goh YJ et al. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity. Int. J. Cancer 1997; 5: 867-73.
39. Pyke C, Kristensen P, Ralfkiaer E et al. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 1991; 51: 4067-71.
40. Petersen LC, Lund LR, Nielsen LS. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem. 1988; 263: 11 189-95.
41. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994; 24: 131-8.
42. Ganesh S, Sier CF, Heerding MM et al. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 1996; 77: 1035-43.
43. Heiss MM, Babic R, Allgayer H et al. The prognostic impact of the urokinase type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur. J. Surg. Oncol. 1996; 22: 74-7.
44. Sier CF, Quax PH, Vloedgraven HJ et al. Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis 1993; 13: 277-88.
45. Maeda K, Chung YS, Sawada T et al. Combined evaluation of urokinase type plasminogen activator and plasminogen activator inhibitor 2 expression in gastric carcinoma. Int. J. Oncol. 1996; 8: 499-503.
46. Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994; 54: 2900-7.
47. Ito H, Yonemura Y, Fujita H et al. Prognostic relevance of urokinase type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch. A Int. J. Pathol. 1996; 427: 487-96.